Capricor Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAPR research report →
Companywww.capricor.com
Capricor Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2.
- CEO
- Linda Marbán
- IPO
- 2007
- Employees
- 160
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $1.30B
- P/E
- -14.22
- P/S
- 0.00
- P/B
- 5.85
- EV/EBITDA
- -10.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.27%
- ROIC
- -40.00%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-105,043,946 · -159.58%
- EPS
- $-2.26 · -96.52%
- Op Income
- $-108,142,130
- FCF YoY
- -174972.15%
Performance & Tape
- 52W High
- $40.37
- 52W Low
- $4.30
- 50D MA
- $31.91
- 200D MA
- $19.26
- Beta
- 0.48
- Avg Volume
- 1.35M
Get TickerSpark's AI analysis on CAPR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Bergmann Anthony | other | 3,000 |
| May 18, 26 | Bergmann Anthony | other | 3,000 |
| May 13, 26 | Litvack Frank | other | 3,937 |
| May 13, 26 | Litvack Frank | other | 3,937 |
| May 1, 26 | Krasney Karen | other | 25,000 |
| May 1, 26 | Krasney Karen | other | 25,000 |
| May 1, 26 | Krasney Karen | sell | 25,000 |
| May 1, 26 | Bergmann Anthony | other | 25,000 |
| May 1, 26 | Bergmann Anthony | other | 25,000 |
| May 1, 26 | Bergmann Anthony | sell | 25,000 |
Our CAPR Coverage
We haven't published any research on CAPR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CAPR Report →